FDA's Next-Generation Review Process: Avoiding the "Crisis Mentality"
This article was originally published in RPM Report
Executive Summary
There are changes coming to FDA's drug review process that, over the long term, should make the system more predictable and increase the chances for a first-cycle approval. Until then, expect a less forgiving agency when it comes to incomplete submissions-and challenges that may threaten the sanctity of priority reviews.